All In Biotech

Drug Trial Radar · NCT05172726

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

58

Actual

Start

Dec 2, 2021

Primary completion

Oct 14, 2026

Study completion Oct 14, 2026

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Dec 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • tapinarof cream, 1%Drug

    applied topically once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Screening up to Week 53
  2. Number of subjects with clinically significant laboratory test abnormalitiesTime frame: Screening up to Week 53
  3. Number of subjects with clinically significant vital signs abnormalitiesTime frame: Screening up to Week 53
  4. Investigator-Assessed Local Tolerability Scale (LTS) ScoresTime frame: Baseline up to Week 52
  5. Subject (or Caregiver)-Assessed Local Tolerability Scale (LTS)Time frame: Baseline up to Week 52

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Northwest Arkansas Clinical Trials Center, PLLC

    Rogers, Arkansas

  • First OC Dermatology

    Fountain Valley, California

  • Mission Dermatology Center

    Rancho Santa Margarita, California

  • RM Medical Research

    Miami Lakes, Florida

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana

  • Options Research Group

    West Lafayette, Indiana

  • Wright State Physicians Pharmacology Translational Unit

    Fairborn, Ohio

  • Oregon Dermatology & Research Center

    Portland, Oregon

  • Dermatology Specialists of Spokane

    Spokane, Washington

  • Dermatology Research Institute Inc.

    Calgary, Alberta, Canada

  • Rejuvenation Laser Dermatology Clinics

    Edmonton, Alberta, Canada

  • Skincare Studio INC

    St. John's, Newfoundland and Labrador, Canada

  • Lynderm Research Inc.

    Markham, Ontario, Canada

  • Alliance Clinical Trials

    Waterloo, Ontario, Canada

  • Whitby Health Centre Dermatology Trials

    Whitby, Ontario, Canada

  • Innovaderm Research, Inc.

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.